[PDF][PDF] Risk allocation versus asset allocation
RG Clarke, H De Silva, BH Wander - The Journal of Portfolio …, 2002 - researchgate.net
Copyright@ Institutional Investor, Inc. All rights reserved. influences, and active risk, which
cannot be explained by marketwide factors. In this framework, active risk represents the …
cannot be explained by marketwide factors. In this framework, active risk represents the …
The limitations of standard deviation as a measure of bond portfolio risk
BH Wander, R D'Vari - The Journal of Wealth Management, 2003 - pm-research.com
The standard deviation of investment returns is widely accepted as the best, and perhaps
only commonly used indicator of portfolio risk in the investment management business. …
only commonly used indicator of portfolio risk in the investment management business. …
[HTML][HTML] ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer
JO Brett, LM Spring, A Bardia, SA Wander - Breast Cancer Research, 2021 - Springer
In metastatic hormone receptor-positive breast cancer, ESR1 mutations are a common
cause of acquired resistance to the backbone of therapy, estrogen deprivation by aromatase …
cause of acquired resistance to the backbone of therapy, estrogen deprivation by aromatase …
How to incorporate hedge funds and active portfolio management into an asset allocation framework
DM Bein, BH Wander - The Journal of Wealth Management, 2002 - pm-research.com
The authors start with the observation that traditional asset allocation processes fail to integrate
the two important sources of portfolio risk: systematic and active. They introduce a new …
the two important sources of portfolio risk: systematic and active. They introduce a new …
Why skillful managers prefer equal-weighted benchmarks
BH Wander - The Journal of Wealth Management, 2003 - pm-research.com
The author investigates the relationship between a manager's ability to add value and the
way the relevant benchmark index is constructed. He first observes that the larger the number …
way the relevant benchmark index is constructed. He first observes that the larger the number …
CDK4/6 Inhibitor Efficacy in ESR1-Mutant Metastatic Breast Cancer
…, AJ Medford, N Wagle, A Bardia, SA Wander - NEJM …, 2024 - evidence.nejm.org
Background In estrogen receptor–positive metastatic breast cancer, ESR1 mutations (ESR1m)
are a common mechanism of acquired resistance to aromatase inhibitors (ArIh). However, …
are a common mechanism of acquired resistance to aromatase inhibitors (ArIh). However, …
A Gene Panel Associated With Abemaciclib Utility in ESR1-Mutated Breast Cancer After Prior Cyclin-Dependent Kinase 4/6-Inhibitor Progression
PURPOSE For patients with hormone receptor–positive (HR+), human epidermal growth
factor receptor 2–negative (HER2–) metastatic breast cancer (MBC), first-line treatment is …
factor receptor 2–negative (HER2–) metastatic breast cancer (MBC), first-line treatment is …
Luck versus Skill: Evaluating an Investment Manager's Track Record
DM Bein, BH Wander - The Journal of Investing, 2002 - pm-research.com
If a manager has an outstanding track record, how can we tell how much this past success
is due to luck versus skill? The complex nature of active portfolio management makes this …
is due to luck versus skill? The complex nature of active portfolio management makes this …
Clinical Implications and Treatment Strategies for ESR1 Fusions in Hormone Receptor-Positive Metastatic Breast Cancer: A Case Series
…, LW Ellisen, A Bardia, SA Wander - The …, 2023 - academic.oup.com
In hormone receptor-positive metastatic breast cancer (HR+ MBC), endocrine resistance is
commonly due to genetic alterations of ESR1, the gene encoding estrogen receptor alpha (…
commonly due to genetic alterations of ESR1, the gene encoding estrogen receptor alpha (…
[PDF][PDF] How to Incorporate Hedge Funds and Active Portfolio Management into an Asset Allocation Framework
B Wander, D Bein - Risk Management Perspectives, Analytic …, 2002 - scholar.archive.org
Arguably, two of the most important decisions a consultant or plan sponsor can make involve
1) the allocation of funds across asset classes and 2) the implementation of the targeted …
1) the allocation of funds across asset classes and 2) the implementation of the targeted …